--- title: "Guotai Group released its first-quarter performance, with a net profit attributable to the parent company of 43.08 million yuan, a year-on-year decrease of 8.23%" type: "News" locale: "en" url: "https://longbridge.com/en/news/237886237.md" description: "According to the Zhitong Finance APP, Guotai Group disclosed its first-quarter report for 2025, showing that the company achieved revenue of 483 million yuan during the reporting period, a year-on-year decrease of 1.26%; net profit attributable to shareholders was 43.08 million yuan, a year-on-year decrease of 8.23%; and net profit excluding non-recurring items was 39.66 million yuan, a year-on-year increase of 17.09%. Basic earnings per share were 0.07 yuan" datetime: "2025-04-28T14:39:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/237886237.md) - [en](https://longbridge.com/en/news/237886237.md) - [zh-HK](https://longbridge.com/zh-HK/news/237886237.md) generator: "portal-rs" --- # Guotai Group released its first-quarter performance, with a net profit attributable to the parent company of 43.08 million yuan, a year-on-year decrease of 8.23% According to the Zhitong Finance APP, Guotai Group (603977.SH) disclosed its first-quarter report for 2025. During the reporting period, the company achieved revenue of 483 million yuan, a year-on-year decrease of 1.26%; net profit attributable to the parent company was 43.08 million yuan, a year-on-year decrease of 8.23%; and net profit excluding non-recurring gains and losses was 39.66 million yuan, a year-on-year increase of 17.09%. Basic earnings per share were 0.07 yuan ### Related Stocks - [603977.CN](https://longbridge.com/en/quote/603977.CN.md) ## Related News & Research - [APT Medical: H1 2026 revenue and profit rose over 25% year-over-year, with strong growth in core segments](https://longbridge.com/en/news/296363764.md) - [TABLE-Asian physical rubber prices - August 19](https://longbridge.com/en/news/296318042.md) - [Ata Turizm Discloses High Non-Compliant Income Under Participation Finance Rules](https://longbridge.com/en/news/296522750.md) - [LongBio Pharma says China regulator accepts LP-003 BLA for seasonal allergic rhinitis](https://longbridge.com/en/news/296541366.md) - [ANALYSIS-Can nicotine pouches drive Big Tobacco's future beyond cigarettes?](https://longbridge.com/en/news/296178056.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**